Physician profile
Feng Liu
NPI 1457449910
$11,962.90
in general payments reported to CMS, 2019-2025
45 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,694 · 2020: $1,501 · 2021: $2,642 · 2022: $2,549 · 2023: $1,451 · 2024: $898 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,663.09 | 2019-2023 | Vumerity, Tysabri, Avonex |
| Amgen INC. | $1,500.63 | 2019-2023 | Aimovig |
| Abbvie INC. | $1,394.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $911.58 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $742.21 | 2019-2023 | Ultomiris |
| Ucb, INC. | $686.88 | 2019-2024 | Rystiggo, Zilbrysq |
| Allergan, INC. | $651.03 | 2019-2022 | |
| Mdd US Operations, LLC | $487.50 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Emd Serono, INC. | $450.90 | 2019-2022 | |
| Lilly USA, LLC | $412.08 | 2019-2023 | Emgality |
| Amneal Pharmaceuticals LLC | $273.55 | 2019-2023 | Rytary |
| Biohaven Pharmaceutical Holding Company Ltd. | $268.62 | 2022 | |
| Genzyme Corporation | $233.36 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $231.06 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $191.33 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.